No black box warning on record for Terazosin

As of the latest FDA labeling reviewed, Terazosin (TERAZOSIN HYDROCHLORIDE) does not carry a black box warning. Standard warnings and precautions still apply — see the full Terazosin medicine page for the complete safety profile.

Other warnings & precautions

WARNINGS Syncope and “First-dose” Effect Terazosin capsules, like other alpha-adrenergic blocking agents, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy. A similar effect can be anticipated if therapy is interrupted for several days and then restarted. Syncope has also been reported with othe

No black box warning on record for Terazosin

Other warnings & precautions

WARNINGS Syncope and “First-dose” Effect Terazosin capsules, like other alpha-adrenergic blocking agents, can cause marked lowering of blood pressure, especially postural hypotension, and syncope in association with the first dose or first few days of therapy. A similar effect can be anticipated if therapy is interrupted for several days and then restarted. Syncope has also been reported with othe

Terazosin Black Box Warning

No black box warning on record for Terazosin

Other warnings & precautions

Terazosin Black Box Warning

No black box warning on record for Terazosin

Other warnings & precautions